NNNN

Anbio Biotechnology
CAPPED RATING

Anbio Biotechnology (NNNN) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A-); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
A-
Factor Score 4.1 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
F
Factor Score 0.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 25.3
EV / EBITDA N/A
Rev Growth YoY 73.9%
Gross Margin 87.2%
Price Return 3M -56.5%
Price Return 12M -83.6%
Catalyst Signal 0.00
Market Cap $166.8M
TTM Revenue $8.6M
Price / Sales 19.3
ROE 27.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) A- (4.1) B+ (3.8) F (0.7) C+ (2.6) C+ (2.8)
2026-11-06 B- (3.0) A (4.3) B+ (3.8) F (0.6) C+ (2.7) B- (2.9)
2026-10-30 B- (3.0) A (4.2) B+ (3.8) F (0.6) C+ (2.7) B- (2.9)
2026-10-23 B- (3.0) A (4.2) B+ (3.8) F (0.6) C+ (2.6) C+ (2.8)
2026-10-16 B- (3.0) A (4.2) B+ (3.8) F (0.6) C+ (2.6) C+ (2.8)
Page 1 of 4